|
Summary Information: Geron Corporation Common Stock NASDAQ:GERN |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
__The following are links to various summary and news pages for __Geron Corporation Common Stock [ GERN ]. __Note: Some Links might not have information for the company. |
|